Inventor · disambiguated record
Toshimitsu Uenaka
Also filed as: UENAKA TOSHIMITSU
7 granted patents·4 pending applications·72 citations·filing 1996–2022
84Inventor score
Top patents by PatentIndex Score
11 records- 0192US10322192B2Eribulin-based antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2018·Granted Jun 18, 2019·18 cites·11 claims
- 0288US10548986B2Eribulin-based antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2017·Granted Feb 4, 2020·9 cites·13 claims
- 0386US7026352B1Physiologically active substancesEISAI CO LTD·Filed 2002·Granted Apr 11, 2006·32 cites·92 claims
- 0482US7667052B2Bioactive substanceEISAI R&D MAN CO LTD·Filed 2005·Granted Feb 23, 2010·7 cites·29 claims
- 0576US2023398228A1Eribulin-based antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2022·Application pending·0 cites
- 0675US8969344B2Method for assay on the effect of vascularization inhibitorMATSUI JUNJI·Filed 2012·Granted Mar 3, 2015·1 cites·4 claims
- 0772US2020297860A1Eribulin-based antibody-drug conjugates and methods of useEISAI R&D MAN CO LTD·Filed 2019·Application pending·0 cites
- 0859US9006240B2Method for assay on the effect of vascularization inhibitorUENAKA TOSHIMITSU·Filed 2006·Granted Apr 14, 2015·1 cites·6 claims
- 0948US5952335AFused polycyclic heterocycle derivativesEISAI CO LTD·Filed 1996·Granted Sep 14, 1999·4 cites·12 claims
- 1042US2008280288A1Assay Method to Predict Sensitivity of Cancer Cell to Anticancer DrugUENAKA TOSHIMITSU·Filed 2005·Application pending·0 cites
- 1133US2017071903A1Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancerEISAI R&D MAN CO LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →